Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass.

Published

Journal Article

UNLABELLED: The Preference and Satisfaction Questionnaire (PSQ) compares patient preference and satisfaction between a 6-month subcutaneous injection and weekly oral tablet for treatment of bone loss. Patients preferred and were more satisfied with a treatment that was administered less frequently, suggesting the acceptability of the 6-month injection for treatment of bone loss. INTRODUCTION: The PSQ compares patient preference and satisfaction between a 6-month subcutaneous injection and a weekly oral tablet for treatment of bone loss. METHODS: Postmenopausal women with low bone mass who enrolled in two separate randomized phase 3 double-blind, double-dummy studies received a 6-month subcutaneous denosumab injection (60 mg) plus a weekly oral placebo or a weekly alendronate tablet (70 mg) plus a 6-month subcutaneous placebo injection. After 12 months, patients completed the PSQ to rate their preference, satisfaction, and degree of bother with each regimen. RESULTS: Most enrolled patients (1,583 out of 1,693; 93.5%) answered >or=1 item of the PSQ. Significantly more patients preferred and were more satisfied with the 6-month injection versus the weekly tablet (P < 0.001). More patients reported no bother with the 6-month injection (90%) than the weekly tablet (62%). CONCLUSION: Patients preferred, were more satisfied, and less bothered with a 6-month injection regimen for osteoporosis.

Full Text

Duke Authors

Cited Authors

  • Kendler, DL; Bessette, L; Hill, CD; Gold, DT; Horne, R; Varon, SF; Borenstein, J; Wang, H; Man, H-S; Wagman, RB; Siddhanti, S; Macarios, D; Bone, HG

Published Date

  • May 2010

Published In

Volume / Issue

  • 21 / 5

Start / End Page

  • 837 - 846

PubMed ID

  • 19657689

Pubmed Central ID

  • 19657689

Electronic International Standard Serial Number (EISSN)

  • 1433-2965

Digital Object Identifier (DOI)

  • 10.1007/s00198-009-1023-x

Language

  • eng

Conference Location

  • England